Levadex is an orally inhaled investigational drug which is used for acute treatment of migraine in adults that targets the pharmacokinetic profiles as described in the patent.
MAP Pharmaceuticals president and CEO Timothy Nelson said they have designed Levadex to overcome the limitations of currently available migraine therapies by combining their formulation capabilities with their proprietary Tempo inhaler, and to target an optimal pharmacokinetic profile for rapid relief of migraine while minimizing side effects.
MAP Pharmaceuticals has partnered with Allergan to co-promote Levadex to neurologists and pain specialists in the US and Canada.